CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis

Fiona C McKay1, Louisa I Swain, Stephen D Schibeci

  • 1Department of Immunology, Westmead Millennium Institute, University of Sydney, Darcy Road, Westmead 2145, Australia.

Insights

Regulatory T cells (Tregs) with low CD127 expression may have impaired survival in multiple sclerosis (MS). Aberrant CD4(+)CD25(-) cells and reduced FoxP3 expression in PPMS suggest altered immune regulation in MS.

Area of Science:

  • Immunology
  • Neuroimmunology

Background:

  • Aberrant regulatory T cell (Treg) populations are implicated in autoimmune diseases.
  • CD127 is a specific marker for the CD4(+)CD25(Hi) Treg subset and is associated with multiple sclerosis (MS).

Purpose of the Study:

  • To investigate the role of CD127 expression and Treg function in different forms of MS.
  • To explore the immunophenotype of regulatory T cells in primary progressive MS (PPMS).

Main Methods:

  • Flow cytometry analysis of T cell subsets (Tregs, CD8(+)CD28(-), NKT cells) and CD127/FoxP3 expression.
  • Correlation analysis of T cell markers with MS subtypes and clinical presentation.

Main Results:

  • Regulatory T cell subsets (Tregs, CD8(+)CD28(-), NKT) exhibit low CD127 levels, potentially impacting survival when IL7 is limited.
  • In PPMS, proportions of CD4(+)FoxP3(+)CD25(Hi) Tregs were not aberrant, but FoxP3 expression per cell trended lower, correlating with suppressor function.
  • The target of Tregs, CD4(+)CD25(-) cells, were in excess in PPMS.
  • A protective CD127 haplotype correlated with higher CD127 expression in PPMS.

Conclusions:

  • Low CD127 expression on certain T cell subsets may contribute to immune dysregulation in MS.
  • Altered Treg function and target cell populations are observed in PPMS, warranting further investigation.
  • The CD127 immunophenotype may represent a therapeutic target in MS.